Insight, China's Pharmaceutical Industry

Company Drug

Novartis Announces First‑In‑Class Phase III Data for Lutetium‑177 Vipivotide Tetraxetan in PSMA‑Positive Metastatic Hormone‑Sensitive Prostate Cancer

Novartis (NYSE: NVS) today disclosed the first data from its Phase III PSMAddition trial of lutetium‑177...

Company Deals

Boston Scientific Announces Nalu Medical Acquisition to Expand Chronic‑Pain Portfolio

Fineline Cube Oct 21, 2025

Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement...

Company Deals

Accord Plasma Completes Acquisition of Prothya Biosolutions, Expanding European Plasma‑Derived Medicinal Product (PDMP) Capabilities

Fineline Cube Oct 21, 2025

Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed...

Company Drug

Changchun High‑Tech Secures NMPA Approval for GenSci139 Bispecific ADC in Advanced Solid Tumors

Fineline Cube Oct 21, 2025

Changchun High‑Tech (SHE: 000661) announced today that its wholly‑owned subsidiary, GenSci (GeneScience Pharmaceutical), has received...

Company Drug

Salubris Shares Promising JK06 ADC Results from ESMO 2025 Clinical Presentation

Fineline Cube Oct 21, 2025

Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced today that its U.S. subsidiary, Salubris Biotherapeutics,...

Company Deals

Advaccine Biotechnology Announces Private Placement of Up to 2.2 Million Shares to Raise RMB 300 Million for Microneedle & Vaccine Development

Fineline Cube Oct 21, 2025

Advaccine Biotechnology (NEEQ: 874055) today disclosed a private placement offering of no more than 2,203,200 shares...

Company Drug

Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR‑Mutated NSCLC

Fineline Cube Oct 21, 2025

Summit Therapeutics, the former China partner of Akeso Inc. (HKG: 9926), announced today that it...

Company Deals

Samsung Bioepis Announces Global ADC Collaboration with Phrontline Biopharma to Advance TJ108

Fineline Cube Oct 21, 2025

Samsung Bioepis Co., Ltd. today announced a strategic, worldwide partnership with Phrontline Biopharma to jointly develop,...

Company Drug

Shanghai Henlius Biotech Secures FDA Orphan Drug Designation for HLX43 in Thymic Epithelial Tumors

Fineline Cube Oct 20, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced today that the U.S. Food and Drug Administration...

Company Drug

CARsgen Announces Promising Phase Ib Results for Satricabtagene Autoleucel Injection in Post‑Surgery Pancreatic Cancer

Fineline Cube Oct 20, 2025

CARsgen Therapeutics Holdings Limited (HKG: 2171) today disclosed interim data from the Phase Ib registrational study...

Company Drug

CSPC Pharmaceutical Secures Breakthrough Therapy Designation for JSKN003 in HER2‑Positive Colorectal Cancer

Fineline Cube Oct 20, 2025

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that JSKN003, a HER2‑bi‑epitope targeted antibody‑drug conjugate (ADC)...

Company Drug

Akeso Announces Landmark Phase III Results for IVONESCIMAB in First‑Line Sq‑NSCLC

Fineline Cube Oct 20, 2025

Akeso Inc. (HKG: 9926) today disclosed the results of its global first‑in‑class bispecific antibody ivonescimab...

Company Drug

Wuhan YZY Biopharma Announces Interim Phase II Results for M701 in Malignant Pleural Effusion

Fineline Cube Oct 20, 2025

Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) today disclosed interim data from its Phase II clinical...

Company Deals

China Isotope & Radiation Corp. Signs MoU With Brazil’s CNEN for Long‑Term Isotope Supply

Fineline Cube Oct 20, 2025

China Isotope & Radiation Corporation (HKG: 1763) announced today that it has signed a Memorandum...

Company Deals

Wuhan Healthgen Announces STAR Market IPO of ORYZOGEN Shares

Fineline Cube Oct 20, 2025

Wuhan Healthgen Biotechnology Corp. (SHA: 688765) today announced that the Shanghai Stock Exchange has approved...

Company Drug

Alphamab Oncology Announces Interim Phase III Results for Anbenitamab in HER2‑Positive Gastric Cancer

Fineline Cube Oct 20, 2025

Alphamab Oncology (HKG: 9966) today disclosed the first interim data from its Phase III study evaluating...

Company Deals

Fosun Kairos Secures Series A Financing to Propel Cell‑Therapy Expansion

Fineline Cube Oct 20, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the Shenzhen Biopharmaceutical Industry Fund...

Company Drug

Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC

Fineline Cube Oct 20, 2025

Multitude Therapeutics, Inc. today released preliminary data from its ongoing Phase I/II, open‑label, multicenter, dose‑escalation and...

Company Drug

Eli Lilly Announces Long‑Term Survival Benefit of Abemaciclib in Early Breast Cancer

Fineline Cube Oct 20, 2025

Eli Lilly & Company (NYSE: LLY) today disclosed the long‑term benefits of abemaciclib in hormone‑receptor‑positive...

Others

Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC

Fineline Cube Oct 20, 2025

Merck KGaA (ETR: MRK) announced that the Chinese National Medical Products Administration (NMPA) has granted...

Insight, China's Pharmaceutical Industry

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Novartis Announces First‑In‑Class Phase III Data for Lutetium‑177 Vipivotide Tetraxetan in PSMA‑Positive Metastatic Hormone‑Sensitive Prostate Cancer

Boston Scientific Announces Nalu Medical Acquisition to Expand Chronic‑Pain Portfolio

Accord Plasma Completes Acquisition of Prothya Biosolutions, Expanding European Plasma‑Derived Medicinal Product (PDMP) Capabilities

Changchun High‑Tech Secures NMPA Approval for GenSci139 Bispecific ADC in Advanced Solid Tumors

Salubris Shares Promising JK06 ADC Results from ESMO 2025 Clinical Presentation

Advaccine Biotechnology Announces Private Placement of Up to 2.2 Million Shares to Raise RMB 300 Million for Microneedle & Vaccine Development

Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR‑Mutated NSCLC

Samsung Bioepis Announces Global ADC Collaboration with Phrontline Biopharma to Advance TJ108

Shanghai Henlius Biotech Secures FDA Orphan Drug Designation for HLX43 in Thymic Epithelial Tumors

CARsgen Announces Promising Phase Ib Results for Satricabtagene Autoleucel Injection in Post‑Surgery Pancreatic Cancer

CSPC Pharmaceutical Secures Breakthrough Therapy Designation for JSKN003 in HER2‑Positive Colorectal Cancer

Akeso Announces Landmark Phase III Results for IVONESCIMAB in First‑Line Sq‑NSCLC

Wuhan YZY Biopharma Announces Interim Phase II Results for M701 in Malignant Pleural Effusion

China Isotope & Radiation Corp. Signs MoU With Brazil’s CNEN for Long‑Term Isotope Supply

Wuhan Healthgen Announces STAR Market IPO of ORYZOGEN Shares

Alphamab Oncology Announces Interim Phase III Results for Anbenitamab in HER2‑Positive Gastric Cancer

Fosun Kairos Secures Series A Financing to Propel Cell‑Therapy Expansion

Multitude Therapeutics Announces Early‑Stage Efficacy Signals for AMT‑116, a First‑In‑Class CD44v9‑Targeting ADC

Eli Lilly Announces Long‑Term Survival Benefit of Abemaciclib in Early Breast Cancer

Merck KGaA Secures NMPA Approval for Erbitux in BRAF‑V600E mCRC

You Missed

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404